Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2012.557 | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | Prof. TAM Lai Shan |
| 2012.476 | Alteration in bone density and microstructure in early rheumatoid arthritis and its relationship with bone erosion: A one-year study by HR-pQCT and MRI | Prof. TAM Lai Shan |
| 2012.558 | An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus | Professor Tam Lai Shan |
| 2013.470 | A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) | Prof Tam Lai Shan |
| 2012.559 | A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists | Prof. TAM Lai Shan |
| 2013.568 | A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. | Prof. TAM Lai Shan |
| 2012.007 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | Prof. TAM Lai Shan |
| 2014.167 | Exploiting the immunomodulatory and anti-inflammatory role of IL35 to modulate inflammation and autoreactive B cell activation in rheumatoid arthritis | Prof. TAM Lai Shan |
| 2023.127 | Machine learning models to quantify and predict radiographic joint damage in rheumatoid arthritis |
Prof. TAM Lai Shan Lai Shan TAM |
| 2020.704 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with rheumatoid arthritis | Prof. TAM Lai Shan |
| 2022.151 | Osteosarcopenia Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and fracture risk in non-osteoporotic patients with immune-mediated inflammatory disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.315 | Axial involvement in patients with Psoriatic Arthritis in Hong Kong – a cross-sectional pilot study |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.343 | AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS COHORT (AXIS) a joint ASAS-GRAPPA project |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.633 | Defining active and structural lesions in the sacroiliac joint and spine by MRI and their predictive utility in axial psoriatic arthritis -a prospective study | Prof Tam Lai Shan |
| 2023.317 | Early identification of axial psoriatic arthritis among patients with psoriasis: a screening study using low-dose computed tomography | Prof. TAM Lai Shan |
| 2022.686 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with psoriatic arthritis | Prof. TAM Lai Shan |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.187 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 教授 |
| 2023.051 | Discovering new post-translational modification patterns for the early diagnosis of rheumatoid arthritis | Prof. TAM Lai Shan |
| 2021.460 | Profiling of Serum Protein Biomarkers in Psoriatic Arthritis–Associated Disease Activity Assessment and Bone Damage |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.189 | Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2021.706 | Effect of Achieving Minimal Disease on the Progression of Subclinical Coronary Atherosclerosis: A Citywide Prospective Cohort Study in Psoriatic Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.306 | Low-dose computed tomography for the detection of structural changes in axial psoriatic arthritis | Prof. TAM Lai Shan |
| 2023.181 | Anti-inflammatory mechanisms of immune-adipose-related Meteorin-like protein (METRNL) in Systemic Lupus Erythematosus | Dr. TAM Lai Shan |
| 2021.401 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2023.355 | Sex- And Gender-based analysis of the Effectiveness of advanced therapies in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2010.191 | Human Papillomavirus infection and cervical intraepithelial neoplasia in patients with systemic lupus erythematosus- the role of toll-like receptors | Professor TAM Lai Shan |
| 2012.478 | Vascular effects of achieving minimal disease activity iin psoriatic arthritis - a 2 year prospetive cohort study | Prof. TAM Lai Shan |
| 2014.052 | Advanced 3-D Bioimaging Technology to improve vertebral fracture prediction in patients with glucocorticoid-induced osteoporosis | Prof. TAM Lai Shan |
| 2010.250 | HMGB1: a danger signal molecule of the innate immune response for the immunopathogenesis of systemic lupus erythematosus | Professor TAM Lai Shan |
| 2011.547 | The role of Receptor for Advanced Glycation End Products (RAGE) in the pathogenesis of systemic Lupus erythematosus (SLE) | Professor TAM Lai Shan |
| 2009.583 | Function and expression profile of the nucleotide-blinding and oligoerization domain (NOD)-2 receptors in systemic lupus erythematosus | Prof Tam Lai Shan |
| 2011.031 | The role of HMGB1 in the pathogenesis of systemic lupus erythematosus | Professor TAM Lai Shan |
| 2008.475 | Innate pathogen recognition in systemic lupus erythematosus: Toll-like receptors and NOD-like receptors | Prof Tam Lai Shan |
| 2016.450 | Cost Effectiveness Analysis of Biologic Therapies for the Treatment of Rheumatoid Arthritis in Hong Kong |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2013.469 | The Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project | Prof. TAM Lai Shan |
| 2017.633 | An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10 |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2016.390 | Assessment of structure changes after 4 years on the second and third metacarpophalangeal joint and distal radius in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT) |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.451 | Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2015.065 | Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | Prof. TAM Lai Shan |
| 2017.389 | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1 | Prof. TAM Lai Shan |
| 2016.037 | Identification and validation of microRNAs associated with inflammation detected by magnetic resonance imaging in patients with early rheumatoid arthritis. |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.697 | Freely circulating microRNAs as biomarkers for fracture and bone loss in female patients with systemic lupus erythematosus on long-term glucocorticoid therapy |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.431 | Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.605 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus | Prof. TAM Lai Shan |
| 2017.446 | A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.451 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.343 | Adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQOL) and Psoriatic Arthritis Quality of Life (PsAQOL) questionnaires in Hong Kong | Prof. TAM Lai Shan |
| 2015.334 | Characterization of the potential role of interleukin-36 (IL-36) in regulating protective and pathogenic B cells in systemic lupus erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2017.261 | The impact of nurse-led programme with and without statin treatment base on traditional cardiovascular risk score or carotid ultrasound on addressing cardiovascular risk in patients with arthritis: a prospective, multicentre, randomised, controlled trial | Prof. TAM Lai Shan |
Page 202 of 265.